Embrace

What Embrace does

Embrace is the consumer brand of Neodyne Biosciences, Inc., a privately held medical device company founded at Stanford University and headquartered in Silicon Valley. Its core product, embrace Active Scar Defense, is an FDA 510(k)-cleared scar therapy system built on proprietary Stress-Shield™ Technology that combines medical-grade silicone with an active tension-offloading mechanism to contract and hold closed incisions together, addressing mechanical skin tension — the root cause of scar formation — rather than treating scars after they form. The portfolio also includes embrace MINIMIZE for existing scars older than six months, embrace Long Wear with an extended 15-day wear cycle, a stretch mark product, and a separate diabetes site care line (CGM, Prevention, Repair) that adapts the same mechano-modulation mechanism for insulin injection and wearable device sites.

The company commercializes primarily through direct-to-consumer e-commerce at embracescartherapy.com, supplemented by a physician referral network of 30+ affiliated plastic surgeons and healthcare systems including Beverly Hills Plastic Surgery Group, Kaiser Permanente, and Stanford Women's Cancer Center. Procedure-specific 60-day kits cover tummy tuck, breast augmentation/lift/reduction/reconstruction, C-section, liposuction, mommy makeover, arm lift, scar revision, cuts and lacerations, and simple excisions/Moh's surgery. Pricing is unit-based (e.g., $46 for diabetes Repair, $66.15 for Prevention) with free U.S. shipping over $50, a 60-day money-back guarantee on unopened product, and an interest-free EmbracePay two-month installment option. International shipping extends to Canada and the United Kingdom. Customer support runs through phone, live chat, and email.

Embrace monetizes as a one-time purchase consumer medical device business rather than a subscription model, with marketing driven by SEO content, social media, patient and physician testimonials, physician referrals, and email/promotional campaigns. The company is led by President and Chief Commercial Officer Kelley Lipman, with clinical credibility anchored by founders Geoffrey Gurtner, Michael Longaker, Reinhold Dauskardt, and Paul Yock, and a 20+ U.S. patent portfolio. Revenue, funding rounds, and headcount are not disclosed in available source material.

Name

Embrace

Legal name

Neodyne Biosciences, Inc.

Website

https://embracescartherapy.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Short description

Embrace (by Neodyne Biosciences) is a privately held medical device company that sells FDA-cleared, silicone-based scar therapy and diabetes site care products built on its patented Stress-Shield tension-offloading technology, distributed direct-to-consumer and through a network of affiliated plastic surgeons across the U.S., Canada, and the U.K.

Ownership category

akta.pro rank

Product category

Scar Therapy Medical Devices

NAICS

Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Wound Closure & Securement (Sutures, Staples, Tissue Adhesives, Skin Closure Strips) (HLAHALAD)

akta.pro secondary industry

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)

Keywords

• Scar therapy products
• Medical-grade silicone devices
• Tension-offloading technology
• Post-surgical scar prevention
• Diabetes site care

Headquarters

HQ city

Fremont

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Marketing or Sales, Personnel, Technology or R&D, Operations

Revenue model

1. Direct Product Sales: One-time purchase model for scar treatment kits and diabetes site care products sold directly to consumers through e-commerce and through physician offices. Products include 60-day treatment kits for various procedures (tummy tuck, breast augmentation, C-section, etc.) and diabetes site care patches (prevention, repair, CGM protection). Each box represents a one-month supply with recommended treatment cycles of 2-4 months.
2. EmbracePay Installment Payments: Split payment option allowing customers to pay for purchases over two monthly installments using debit or credit card. Interest-free financing for qualified purchases. This drives higher average order values by reducing upfront cost barrier.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

Embrace develops and sells FDA-cleared silicone scar therapy devices built on its patented Stress-Shield Technology, which actively contracts and holds closed incisions together to relieve skin tension during healing. Products are sold as procedure-specific 60-day treatment kits (Tummy Tuck, Breast Augmentation/Lift/Reduction/Reconstruction, C-Section, Liposuction, Mommy Makeover, Arm Lift, Scar Revision, Cuts and Lacerations, Simple Excisions & Moh's), plus a separate diabetes site care line for insulin and CGM users.

Product overview

Embrace (by Neodyne Biosciences) is a unified portfolio of scar therapy and diabetes site care products, all built on its patented Stress-Shield Technology platform with FDA-clearance. The core offering is embrace Active Scar Defense, an FDA-cleared scar prevention system that relieves tension around incisions to prevent raised scars. This technology is packaged into procedure-specific kits (Tummy Tuck, Breast Augmentation, Breast Lift, Breast Reduction, Breast Reconstruction, Mommy Makeover, C-Section, Liposuction, Arm Lift, Scar Revision, Cuts and Lacerations, Simple Excisions & Moh's) and the embrace Long Wear variant with extended 15-day wear. A second product line, embrace MINIMIZE, targets existing scars older than 6 months with the same Stress-Shield silicone technology. A separate diabetes site care division offers embrace patches for CGM protection, prevention, and repair of injection site damage from MDIs and insulin pumps, using the same mechano-modulation tension-offloading mechanism but adapted for wearable device site management.

Differentiator

Problem solved

Functional benefit

Products and services

• embrace Active Scar Defense
• embrace MINIMIZE
• embrace Long Wear
• embrace for CGM
• embrace for Prevention
• embrace for Repair
• embrace Stretch Marks

Quantifiable outcome

• 92% of doctors and patients rated embrace-treated scars as better than competing treatments
• +6 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration7 records

Feature4 records

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Mederma (HRA Pharma): Mederma is a top-selling OTC scar gel brand (cepalin + onion extract) used post-surgery and for scar revision, competing with Embrace on retail pharmacy shelves and consumer mindshare.
• Biodermis: Biodermis is a direct competitor in medical-grade silicone scar therapy, offering silicone sheets, gels, and Epi-Derm products for post-surgical and trauma scar treatment across consumer and clinical channels.
• ScarAway (by Perrigo): ScarAway is a leading OTC silicone scar-treatment brand offering sheets and gel for surgical, injury, and keloid scars, directly competing with Embrace in the same end-customer segment at a lower price point.

Emerging players

• Organogenesis: Organogenesis is a regenerative medicine company with wound-care and surgical biologics products (Apligraf, Dermagraft), competing in advanced wound healing and surgical recovery adjacencies.
• Aroa Biosurgery: Aroa Biosurgery develops regenerative soft-tissue repair and wound-healing products using proprietary extracellular matrix technology, overlapping with Neodyne's biologic/regenerative wound-therapy positioning.

Broad incumbents

• Mölnlycke Health Care: Mölnlycke is a global wound-care and surgical-solutions leader offering Mepilex silicone dressings and surgical incision-management products, competing in the same clinical end markets as Embrace.
• Coloplast (Wound Care): Coloplast is a global wound-care and ostomy-care incumbent with silicone-based dressings and post-surgical skin care products, overlapping with Embrace's wound/skin-care positioning.
• Integra LifeSciences: Integra LifeSciences is a large diversified medical device company with a meaningful wound-care and regenerative tissue portfolio, competing in surgical and post-surgical dressings across hospital channels.
• 3M (Health Care / Nexcare): 3M's Health Care division offers Nexcare scar therapy and a broad range of surgical tapes and dressings, competing in OTC scar treatment and surgical securement categories.
• Smith & Nephew (Wound Care): Smith & Nephew is a global wound-care incumbent offering advanced dressings, negative-pressure wound therapy, and post-surgical scar-management products across hospital and DTC channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/neodyneembrace
• YouTubeyoutube.com/user/EmbraceScarTherapy
• Facebookfacebook.com/embracescartherapy
• Instagraminstagram.com/embracescartherapy
• Pinterestpinterest.com/embracescar
• LinkedInlinkedin.com/company/neodyne-biosciences-inc

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Embrace